Predicting failure of glyburide therapy in gestational diabetes

J Perinatol. 2016 May;36(5):347-51. doi: 10.1038/jp.2015.216. Epub 2016 Jan 21.

Abstract

Objective: We sought to develop a prediction model to identify women with gestational diabetes (GDM) who require insulin to achieve glycemic control.

Study design: Retrospective cohort of all singletons with GDM treated with glyburide from 2007 to 2013. Glyburide failure was defined as reaching glyburide 20 mg day(-1) and receiving insulin. Glyburide success was defined as any glyburide dose without insulin and >70% of visits with glycemic control. Multivariable logistic regression analysis was performed to create a prediction model.

Result: Of the 360 women, 63 (17.5%) qualified as glyburide failure and 157 (43.6%) as glyburide success. The final prediction model for glyburide failure included prior GDM, GDM diagnosis ⩽26 weeks, 1-h glucose challenge test ⩾228 mg dl(-1), 3-h glucose tolerance test 1-h value ⩾221 mg dl(-1), ⩾7 postprandial blood sugars >120 mg dl(-1) in the week glyburide started and ⩾1 blood sugar >200 mg dl(-1). The model accurately classified 81% of subjects.

Conclusion: Women with GDM who will require insulin can be identified at the initiation of pharmacological therapy.

MeSH terms

  • Adult
  • Blood Glucose / analysis
  • Cohort Studies
  • Diabetes, Gestational* / diagnosis
  • Diabetes, Gestational* / drug therapy
  • Dose-Response Relationship, Drug
  • Drug Monitoring / methods
  • Drug Resistance
  • Female
  • Glucose Tolerance Test / methods*
  • Glyburide* / administration & dosage
  • Glyburide* / adverse effects
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects
  • Insulin / therapeutic use*
  • Medical History Taking / methods
  • Predictive Value of Tests
  • Pregnancy
  • Prognosis
  • Retrospective Studies
  • Treatment Failure
  • United States

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Glyburide